Tyrosine kinase inhibitors for suppression of tumorigenic growth of Ras-transformed cells: PAK-ing in the signals.
Gallick
G E
GE
Department of Cancer Biology, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002455:Cell Division; D002461:Cell Line, Transformed; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015689:Oncogene Protein p21(ras) / Q000037:antagonists & inhibitors*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D015398:Signal Transduction; D054462:p21-Activated Kinases; D019061:src-Family Kinases / Q000037:antagonists & inhibitors*
C108123:4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; D000970:Antineoplastic Agents; D011720:Pyrazoles; D011743:Pyrimidines; D019061:src-Family Kinases; D017346:Protein Serine-Threonine Kinases; D054462:p21-Activated Kinases; D015689:Oncogene Protein p21(ras)